Comparison of patients with high CAR exposure and low LDH vs patients with low CAR exposure and low LDH
| Variable . | CARlow/LDHlow . | CARhigh/LDHlow . | P value . |
|---|---|---|---|
| n | 32 | 27 | |
| Max ICANS, n (%) | .001 | ||
| 0 | 22 (68.8) | 7 (25.9) | |
| 1-2 | 5 (15.6) | 16 (59.3) | |
| 3-4 | 5 (15.6) | 4 (14.8) | |
| Tocilizumab = yes, n (%) | 19 (59.4) | 25 (92.6) | .009 |
| Cumulative steroid dose, median (IQR) | 20 (0-121) | 150 (35-210) | .016 |
| CRS grade 2-3, n (%) | 14 (43.8) | 20 (74.1) | .037 |
| Variable . | CARlow/LDHlow . | CARhigh/LDHlow . | P value . |
|---|---|---|---|
| n | 32 | 27 | |
| Max ICANS, n (%) | .001 | ||
| 0 | 22 (68.8) | 7 (25.9) | |
| 1-2 | 5 (15.6) | 16 (59.3) | |
| 3-4 | 5 (15.6) | 4 (14.8) | |
| Tocilizumab = yes, n (%) | 19 (59.4) | 25 (92.6) | .009 |
| Cumulative steroid dose, median (IQR) | 20 (0-121) | 150 (35-210) | .016 |
| CRS grade 2-3, n (%) | 14 (43.8) | 20 (74.1) | .037 |
Patients with low CAR19 exposure in the lower risk group have improved safety characteristics including less CRS and ICANS and lower total steroid use. P values as assigned by unadjusted Kruskal-Wallis test.
IQR, interquartile range; Max, maximum.